Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment approach consisting of dendritic cell (DC) vaccination to prime tumor-specific T cells, and a strategy to reprogram the desm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Sai Ping, van Montfoort, Nadine, Kinderman, Priscilla, Lukkes, Melanie, Klaase, Larissa, van Nimwegen, Menno, van Gulijk, Mandy, Dumas, Jasper, Mustafa, Dana A M, Lievense, Sanne L A, Groeneveldt, Christianne, Stadhouders, Ralph, Li, Yunlei, Stubbs, Andrew, Marijt, Koen A, Vroman, Heleen, van der Burg, Sjoerd H, Aerts, Joachim, van Hall, Thorbald, Dammeijer, Floris, van Eijck, Casper H J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373331/
https://www.ncbi.nlm.nih.gov/pubmed/32690771
http://dx.doi.org/10.1136/jitc-2020-000772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373331/
https://www.ncbi.nlm.nih.gov/pubmed/32690771
http://dx.doi.org/10.1136/jitc-2020-000772

Ejemplares similares